Bob McNally CEO GeoVax joined the Board of Directors in December 2006 and was appointed as President and Chief Executive Officer effective April 1, 2008. From 2000 to March 2008, Dr. McNally served as Chief Executive Officer of Cell Dynamics LLC, a cGMP laboratory services company.
(Encore) Original Broadcast August 3, 2011
Atlanta Business Radio on Business RadioX TM Network
Host: Amy Otto & Lee Kantor
GeoVax’s mission is to develop, manufacture, test and license vaccines to combat significant human diseases for which no vaccines presently exist. Our first target is HIV/AIDS for which our vaccine technology has demonstrated promising preventative as well as therapeutic potential.
In 2001, GeoVax Inc. was established in Atlanta, Georgia to develop highly promising vaccine technologies for preventing AIDS caused by HIV-1 (Human Immunodeficiency Virus-1 or AIDS virus). Our HIV/AIDS vaccine technologies and extensive patent filings evolved over 15 years through a collaboration headed by Dr. Harriet Robinson at Emory University in Atlanta with researchers at the U.S. National Institutes of Health (NIH) and Centers for Disease Control & Prevention (CDC).
Previously, Dr. McNally was Senior Vice President of Clinical Research for CryoLife, Inc., a pioneering company in transplantable human tissues. Dr. McNally is a Fellow of the American Institute for Medical and Biological Engineering, serves on the advisory boards of the Petit Institute for Bioengineering and Dupree College of Management at the Georgia Institute of Technology, and is a former Chairman of Georgia Bio, a trade association.
Dr. McNally graduated with a Ph.D. in biomedical engineering from the University of Pennsylvania. The Board of Directors has concluded that Dr. McNally should serve on its Board of Directors by virtue of his prior business and scientific experience, including his experience as Chief Executive Officer of Cell Dynamics, LLC and as Senior Vice President of Clinical Research for CryoLife, Inc., and due to his intimate involvement with the Company’s ongoing operations as its President and Chief Executive Officer.
